NLRP3 and diabetic cardiomyopathy: Metformin, the most widely used drug for treating T2D (Forslund et al., 2017), can inhibit NLRP3 by activating AMPK (AMP-activated protein kinase), thus increasing autophagy activity to promote the clearance of inflammasomes via inhibiting the mTOR pathway and alleviating the symptoms in diabetic cardiomyopathy (Yang et al., 2019a; Figure 3).